Direct Gene Transfer of a Plasmid Carrying the Herpes Simplex Virus-Thymidine Kinase Gene (HSV-TK) in Transplanted Murine Melanoma: In Vivo Study

European Journal of Cancer

Volumn 32, Issue 4, 1996, Pages 691-695

  Soubrane, C ^a   Mouawad, R ^a   Rixe, O ^a   Calvez, V ^a   Ghoumari, A ^a   Verola, O ^b   Weil, M ^a   Khayat, D ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Gene therapy; HSV TK gene; In vivo; Malignant melanoma; Vectors

Indexed keywords

GANCICLOVIR; LIPOSOME; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS; MALE; MELANOMA B16; MOUSE; NECROSIS; NONHUMAN; PLASMID; PRIORITY JOURNAL; VIRUS GENE;

ANIMALS; GENE TRANSFER TECHNIQUES; GENES, VIRAL; GENETIC VECTORS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SIMPLEXVIRUS; THYMIDINE KINASE; VIRAL STRUCTURAL PROTEINS;

EID: 0030012741     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00605-2     Document Type: Article

References (25)

1. Legha SS. Current therapy for melanoma. Semin Oncol 1989, 16, 34-44.
2. Gundersen S. Dacarbazine, vindesine and cisplatinum combination chemotherapy in advanced malignant melanoma: a phase II study. Cancer Treat Rep 1987, 71, 997-999.
3. Rosenberg SA, Lotze MT, Yang JC. Combination therapy with interleukin-2 and α-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989, 12, 1863-1874.
4. Kirkwood JM. Studies of interferons in the therapy of melanoma. Semin Oncol 1991, 18, 83-89.
5. Shiloni E, Pouillart P, Sanssens J. Sequential administration of recombinant human Interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study. J Clin Oncol 1991, 9, 1687-1691.
6. Khayat D, Borel C, Tourani JM, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993, 11, 2173-2180.
7. Colbère-Garapin F, Chousterman S, Horodniceanu F, Kourilsky P, Garapin AC. Cloning of the active thymidine kinase gene of herpes simplex virus type 1 in Escherichia coli K-12. Proc Natl Acad Sci USA 1979, 76, 3755-3759.
8. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990, 82, 297-300.
9. Huber BE, Richards CA, Krenitsky TA. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma; an innovative approach for cancer therapy. Proc Natl Acad Sci USA 1991, 88, 8039-8043.
10. Culver KW, Ram Z, Wallbridger S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992, 256, 1550-1552.
11. Vile RG, Hart IR. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 1993, 53, 962-967.
12. Temin MT. Retrovirus vectors: promise and reality. Science 1989, 246, 983.
13. Quantin B, Perricaudet L, Tagbakash S. Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci USA 1992, 89, 2581-2584.
14. Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 1993, 67, 5911-5921.
15. Nabel GJ, Nabel EG, Yang ZY, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993, 90, 11,307-11,311.
16. Davis HL, Demeneix BA, Quantin B, Coulombe J, Whalen RG. Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. Hum Gene Ther 1993, 4, 733-740.
17. Hickman MA, Malone RW, Lehmann-Bruinsma K, et al. Gene expression following direct injection of DNA into liver. Hum Gene Ther 1994, 5, 1477-1483.
18. Vile RG, Hart IR. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 1993, 53, 3860-3864.
19. Plautz GE, Yang ZY, Wu BY, Gao X, Huang L, Nabel GJ. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 1993, 90, 4645-4649.
20. Ezzeddine ZD, Martuza RL, Platika D, et al. Selective killing of glioma cells in culture and in vivo by retrovirus-transfer of the herpes simplex virus thymidine kinase gene. New Biol 1991, 3, 608-614.
21. Takamiya RL, Short MP, Ezzeddine ZD, Moolten FL, Breakefield XO, Martuza RL. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J Neurosci Res 1992, 33, 493-503.
22. Kolberg R. Gene therapists test puzzling "bystander effect" [News]. NIH Res 1992, 4, 68-74.
23. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993, 53, 5274-5283.
24. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994, 54, 6228-6234.
25. Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 1988, 10, 490-494.